PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

5AM Ventures

San Francisco, CA5AM-VENTURES
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

No summary available yet.

Classification
Slug5am-ventures
HQSan Francisco, CA
Stage FocusSeries A through C in life sciences, with heavy emphasis …
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

5AM is one of the smarter life sciences funds that actually gets the tech side of biotech. They're not just former Big Pharma folks writing checks — they understand computational platforms and can help you navigate both the science and the business. The partners are genuinely helpful post-investment and have solid pharma connections for partnerships. However, they're picky as hell and move slower than software VCs, so don't expect quick decisions. They also tend to want meaningful board seats and operational input, which is great if you want the help but can feel heavy-handed if you don't.

KEY TAKEAWAYS
  • Best for: computational biology and AI-driven life sciences companies needing scientific credibility
  • Watch out for: slower decision-making and hands-on board involvement expectations
  • Known for: strong pharma networks and operational support for complex regulatory pathways
Investment Thesis

5AM Ventures focuses on transformational life sciences companies, particularly those leveraging computational approaches, AI/ML, and novel platforms in therapeutics, diagnostics, and healthcare infrastructure. They invest in companies that can benefit from their deep scientific expertise and operational support in navigating complex regulatory and commercial pathways.

Stage & Sector Focus

Series A through C in life sciences, with heavy emphasis on computational biology, AI-driven drug discovery, diagnostics, and healthcare IT. Portfolio skews toward platform companies rather than single-asset biotechs, typically writing $3-15M initial checks.

Notable Portfolio
10x GenomicsGuardant HealthVeracyteZymergenRecursion PharmaceuticalsinsitroRoivant SciencesDesktop Health
Key Partners
Kush Parmar
Managing Director

Former McKinsey partner focused on life sciences and healthcare. Known for his operational expertise and strong network in pharma/biotech. Founders appreciate his practical approach to building scalable life sciences businesses.

Andrew Schiff
Managing Director

Previously at Flagship Pioneering and BCG, with deep computational biology expertise. Strong technical background helps him evaluate complex platform technologies. Respected for his scientific rigor and founder-friendly approach.

Chinedu Echeruo
Principal

Former entrepreneur (sold HopStop to Apple) turned investor. Brings product and scaling experience to healthcare IT and digital health investments. Known for being hands-on with go-to-market strategy.

Have a specific question about 5AM Ventures?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1